MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: Experience on seven patients

Annals of Oncology

Volumn 21, Issue 6, 2009, Pages 1173-1178

  Derenzini, E ^a   Fina, M P ^a   Stefoni, V ^a   Pellegrini, C ^a   Venturini, F ^a   Broccoli, A ^a   Gandolfi, L ^a   Pileri, S ^a   Fanti, S ^b   Lopci, E ^b   Castellucci, P ^b   Agostinelli, C ^a   Baccarani, M ^a   Zinzani, P L ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Chemotherapy; Langerhans cell histiocytosis; MACOP B

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FOLINIC ACID; IFOSFAMIDE; MELPHALAN; METHOTREXATE; PREDNISONE; STEROID; VINBLASTINE; VINCRISTINE; FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; BONE DISEASE; CLINICAL ARTICLE; DISEASE CLASSIFICATION; DRUG EFFICACY; FEMALE; FOLLOW UP; HISTIOCYTOSIS X; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RELAPSE; SHORT COURSE THERAPY; TREATMENT RESPONSE; ADOLESCENT; DIAGNOSTIC USE; DISEASE COURSE; EVALUATION STUDY; HISTIOCYTOSIS, LANGERHANS-CELL; MIDDLE AGED; REMISSION; RETROSPECTIVE STUDY; SCINTISCANNING; YOUNG ADULT;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DOXORUBICIN; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; LEUCOVORIN; MALE; METHOTREXATE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PREDNISONE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; VINCRISTINE; YOUNG ADULT;

EID: 77953986335     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp455     Document Type: Article

References (23)

1. Stockschlaeder M, Sucker C. Adult Langerhans cell histiocytosis. Eur J Haematol 2006; 76: 363-368.
2. Arico M, Girchikofsky M, Genereau T et al. Langerhans cell histiocytosis in adults. Report from the International Registry of the Histiocyte Society. Eur J Cancer 2003; 39: 2341-2348.
3. Chu T, D'Angio GJ, Favara BE et al. Histiocytosis syndromes in children. Writing Group of the Histiocyte Society. Lancet 1987; 2(8549): 41-42.
4. Howarth DM, Gilchrist GS, Mullan BP et al. Langerhans cell histiocytosis: diagnosis, natural history, management, and outcome. Cancer 1999; 85: 2278-2290.
5. Gadner H, Heitger A, Grois N et al. Treatment strategy for disseminated Langerhans cell histiocytosis. DAL-HX 83 Study Group. Med Pediatr Oncol 1994; 23: 72-80.
6. Gadner H, Grois N, Arico M et al. A randomized trial of treatment for multisystem Langerhans cell histiocytosis. J Pediatr 2001; 138: 728-734.
7. Gadner H, Grois N, Potscher U et al. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood 2008; 111(5): 2556-2562.
8. Klimo P, Connors JM. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 1985; 102: 596-602.
9. Zinzani PL, Stefoni V, Tani M et al. MACOP-B regimen followed by involved-field radiation therapy in early-stage aggressive non-Hodgkin's lymphoma patients: 14-year update results. Leuk Lymphoma 2001; 42(5): 989-995.
10. Zinzani PL, Martelli M, De Renzo A et al. Primary mediastinal large B-cell lymphoma with sclerosis: a clinical study of 89 patients treated with MACOP-B chemotherapy and radiation therapy. Haematologica 2001; 86: 187-191.
11. Favara BE, Feller AC, Pauli M et al. Contemporary classification of histiocytic disorders. The WHO Committee on Histiocytic/Reticulum Cell Proliferations. Reclassification Working Group of the Histiocyte Society. Med Pediatr Oncol 1997; 29: 157-166.
12. Baumgartner I, von Hochstetter A, Baumert B et al. Langerhans'-cell histiocytosis in adults. Med Pediatr Oncol 1997; 28: 9-14.
13. Morimoto A, Ikushima S, Kinugawa N et al. Improved outcome in the treatment of pediatricmultifocalLangerhans cellhistiocytosis. Results fromthe JapanLangerhans Cell Histiocytosis Study Group-96 protocol study. Cancer 2006; 107: 613-619.
14. Goo HW, Yang DH, Ra YS et al. Whole-body MRI of Langerhans cell histiocytosis: comparison with radiography and bone scintigraphy. Pediatr Radiol 2006; 36: 1019-1031.
15. Phillips M, Allen C, Gerson P, McKlain K. Comparison of FDG-PET scans to conventional radiography and bone scans in management of Langerhans cell histiocytosis. Pediatr Blood Cancer 2009; 52: 97-101.
16. Zinzani PL, Tani M, Molinari AL et al. Ifosfamide, epirubicin, and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients. Haematologica 2002; 87: 816-821.
17. Philip T,ArmitageJO,SpitzerG et al. High-dose therapyand autologousbonemarrow transplantation after failure of conventional chemotherapy in adults with intermediate and high-grade non-Hodgkin lymphoma. N Engl J Med 1987; 316: 1493-1498.
18. Ichikawa K, Nomura S, Ishii K et al. Autologous stem cell transplantation for refractory Langerhans' cell histiocytosis. Bone Marrow Transplant 2007; 40: 807-808.
19. Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a Standard Regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002-1006.
20. Pfreundschuh M, Trumper L, Kloess M et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004; 104: 626-633.
21. Verdonck LF, Notenboom A, De Jong DD et al. Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). Blood 2007; 109(7): 2759-2766.
22. Minkov M, Grois N, Heitger A et al. Response to initial treatment of multisystem Langerhans cell histiocytosis: an important prognostic indicator. Med Pediatr Oncol 2002; 39: 581-585.
23. Minkov M, Grois N, Heitger A et al. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL HX Study Group. Klin Padiatr 2000; 212: 139-144.